Active Wound Coverings: Bioengineered Skin and Dermal Substitutes

Surgical Clinics of North America

Volumn 90, Issue 6, 2010, Pages 1237-1255

  Límová, Markéta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allogeneic; Autologous; Bioengineered skin; Extracellular matrix; Skin substitutes

Indexed keywords

BIOBRANE;

BIOENGINEERING; CADAVER; EXTRACELLULAR MATRIX; HUMAN; PRIORITY JOURNAL; REVIEW; SKIN ALLOGRAFT; SKIN CULTURE; SKIN TRANSPLANTATION; TISSUE ENGINEERING; WOUND DRESSING;

BIOCOMPATIBLE MATERIALS; BIOENGINEERING; BIOLOGICAL DRESSINGS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; RISK ASSESSMENT; SKIN; SKIN TRANSPLANTATION; SKIN ULCER; SKIN, ARTIFICIAL; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 78149421751     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.08.004     Document Type: Review

References (114)

1. Winter G.D. Formation of scab and the rate of epithelialization of superficial wounds in the skin of the young domestic pig. Nature 1962, 193:293-294.
2. Hinman C.D., Maibach H.I. Effect of air exposure and occlusion on experimental human skin wounds. Nature 1963, 200:377-378.
3. Ovington L. The art and science of wound dressings in the twenty-first century. Wound healing 2005, 45:587-598. Taylor & Francis, Boca Raton (FL). A. Falabella, R. Kirsner (Eds.).
4. Shores J.T., Gabriel A., Gupta S. Skin substitutes and alternatives: a review. Adv Skin Wound Care 2007, 20:493-508.
5. Pruitt B.A., Levine N.S. Characteristics and uses of biologic dressings and skin substitutes. Arch Surg 1984, 119:312-322.
6. Cullen B., Watt P.W., Lundqvist C., et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol 2002, 34:1544-1556.
7. Mian M., Beghe F., Mian E. Collagen as a pharmacological approach in wound healing. Int J Tissue React 1992, 14:S1-S9.
8. Harper C. Permacol: clinical experience with a new biomaterial. Hosp Med 2001, 62:90-95.
9. Haslik W., Kamolz L.-P., Nathschlager G., et al. First experiences with the collagen-elastin matrix Matriderm as a dermal substitute in severe burn injuries of the hand. Burns 2007, 33:364-368.
10. Ryssel H., Gazyakan E., Germann G., et al. The use of Matriderm in early excision and simultaneous autologous skin grafting in burns - a pilot study. Burns 2008, 34:93-97.
11. van Zuijlen P.P., Lamme E.N., van Galen M.J., et al. Long term results of a clinical trial on dermal substitution. A light microscopy and Fourier analysis based evaluation. Burns 2002, 28:151-160.
12. Haslik W., Kamolz L.P., Manna F., et al. Management of full-thickness skin defects in the hand and wrist region: first long-term experiences with the dermal matrix Matriderm. J Plast Reconstr Aesthet Surg 2008, 63:360-364.
13. van Zuijlen P.P., van Trier A.J., Vloemans J.F., et al. Graft survival and effectiveness of dermal substitution in burns and reconstructive surgery in a one-stage grafting model. Plast Reconstr Surg 2000, 106:615-623.
14. Kolokythas P., Vogt P.M., Boorboor P., et al. Simultaneous coverage of full thickness burn wounds with Matriderm dermal substitute and split thickness skin grafting. Burns 2007, 33:S72.
15. Hodde J.P., Ernst D.M., Hiles M.C. An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix. J Wound Care 2005, 14:23-25.
16. Oasis Wound Matrix Web site Available at:, Accessed May 23, 2010. http://www.oasiswoundmatrix.com.
17. Mostow E.N., Haraway G.D., Dalsing M., et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg 2005, 41:837-843.
18. Biobrane: biocomposite temporary wound dressings Available at:, Accessed May 23, 2010. http://www.udllabs.com/burn_care/biobrane.aspx.
19. Aubrey Inc Available at:, Accessed May 23, 2010. http://www.aubreyinc.com/awbat.html.
20. Woodroof E.A. The Search for an ideal temporary skin substitute: AWBAT. Eplasty 2009, 9:95-104.
21. Integra Dermal Regeneration Integra LifeSciences Corporate Web site Available at:, Accessed May 23, 2010. http://www.integra-ls.com/home/.
22. Stern R., McPherson M., Longaker M.T. Histologic study of artificial skin used in the treatment of full thickness thermal injury. J Burn Care Rehabil 1990, 11:7-13.
23. Heimbach D., Luteman A., Burke J.F., et al. Artificial dermis for major burns: a multi-center randomized clinical trial. Ann Surg 1988, S208:313-320.
24. Fitton A.R., Drew P., Dickson W.A. The use of a bilaminate artificial skin substitute (Integra) in acute resurfacing of burns: an early experience. Br J Plast Surg 2001, 54:208-212.
25. Klein M.B., Engrav L.H., Holmes J.H., et al. Management of facial burns with a collagen/glycosaminoglycan skin substitute-prospective experience with 12 consecutive patients with large, deep facial burns. Burns 2005, 31:257-261.
26. Michaeli D., McPherson M. Immunologic study of artificial skin used in the treatment of thermal injuries. J Burn Care Rehabil 1990, 11:21-26.
27. Phillips P.L., Yan Q., Sampson E., et al. Effects of antimicrobial agents on an in vitro biofilm model of skin wounds. Advances in wound care 2010, vol. 1:299-304. 6, Liebert, Columbus (OH). C.K. Sen (Ed.).
28. Sapadin A.N., Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006, 54:258.
29. Shanmuganathana S., Shanumugasundarama N., Adhirajana N., et al. Preparation and characterization of chitosan microspheres for doxycycline delivery. Carbohydr Polym 2008, 73:201.
30. Shea L.D., Smiley E., Bonadio J., et al. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol 1999, 17:551-554.
31. Murphy W.L., Mooney D.J. Controlled delivery of inductive proteins, plasmid DNA and cells from tissue engineering matrices. J Periodontal Res 1999, 34:413-419.
32. Luu Y.K., Kim K., Hsiao B.S., et al. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J Control Release 2003, 89:341-353.
33. Snyder R.J., Simonson D.A. Cadaveric allograft as adjunct therapy for nonhealing ulcers. J Foot Ankle Surg 1999, 38:93-101.
34. Barnett J.R., McCauley R.L., Schutzler S., et al. Cadaver donor discards secondary to serology. J Burn Care Rehabil 2001, 22:124-127.
35. Mathur M., De A., Gore M. Microbiological assessment of cadaver skin grafts received in a Skin Bank. Burns 2008, 35:104-106.
36. Wainwrigth D.J. Use of an acellular allograft dermal matrix (Alloderm) in the management of full-thickness burns. Burns 1995, 21:243-248.
37. Munster A.M., Smith-Meek M., Shalom A. Acellular allograft dermal matrix: immediate or delayed epidermal coverage?. Burns 2001, 27:150-153.
38. Brigido S.A., Boc S.F., Lopex R.C. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics 2004, S27:145-149.
39. Rosales M.A., Bruntz M., Armstrong D.G. Gamma-irradiated human skin allograft: a potential treatment of modality for lower extremity ulcers. Int Wound J 2004, 1:201-206.
40. Onur R., Singla A. Solvent-dehydrated cadaveric dermis: a new allograft for pubovaginal sling surgery. Int J Urol 2005, 12:801-805.
41. Supp D.M., Karpinski A.C., Boyce S.T. Expression of human beta-defensins HBD-1, HBD-2, and HBD-3 in cultured keratinocytes and skin substitutes. Burns 2004, 30:643-648.
42. Schurr M.J., Foster K.N., Centanni J.M., et al. Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute. J Trauma 2009, 66:866-874.
43. Dermagraft Web site Available at:, Accessed May 23, 2010. http://www.dermagraft.com/.
44. Mansbridge J., Liu K., Patch R., et al. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng 1998, 4:403-414.
45. Harding K.G., Moore K., Phillips T.J. Wound chronicity and fibroblast senescence-implications for treatment. Int Wound J 2005, 2:364-368.
46. Gentzkow G., Jensen J., Pollak R., et al. Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. Wounds 1999, 11:77-84.
47. Gentzkow G.D., Iwasaki S., Hershon K., et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996, 19:350-354.
48. Marston W.A., Hanft J., Norwood P., et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003, 26:1701-1705.
49. Omar A.A., Mavor A.I., Jones A.M., et al. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovasc Surg 2004, 27:666-672.
50. Omar A.A., Mavor A.I., Homer-Vanniasinkam S. Evaluation of dermagraft as an alternative to grafting for open fasciotomy wounds. J Wound Care 2002, 11:96-97.
51. TransCyte human fibroblast-derived temporary skin; Web site. Advanced BioHealing Inc Available at:, Accessed May 23, 2010. http://transcyte.com/.
52. Bello Y.M., Falabella A.F., Eaglstein W.H. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol 2001, 2:305-313.
53. Purdue G.F., Hunt J.L., Still J.M., et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997, 18:52-57.
54. Kumar R.J., Kimble R.M., Boots R., et al. Treatment of partial-thickness burns: a prospective, randomized trial using TransCyte. ANZ J Surg 2004, 74:622-626.
55. Boyd M., Flasza M., Johnson P.A., et al. Integration and persistence of an investigational human living skin equivalent (ICX-SKN) in human surgical wounds. Regen Med 2007, 2:369-376.
56. Still J., Glat P., Silverstein P., et al. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns 2003, 29:837-841.
57. Sibbald R.G., Zuker R., Coutts P., et al. Using a dermal skin substitute in the treatment of chronic wounds secondary to recessive dystrophic epidermolysis bullosa: a case series. Ostomy Wound Manage 2005, 51:22-46.
58. Hasegawa T., Suga Y., Mizoguchi M., et al. Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 2004, 50:803-804.
59. Apligraf Web site Available at:, Accessed May 23, 2010. http://www.apligraf.com/professional/index.html.
60. Trent J.F., Kirsner R.S. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. Int J Clin Pract 1998, 52:408-413.
61. Falanga V., Margolis D., Alvarez O., et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 1998, 134:293-300.
62. Falanga V., Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 1999, 7:201-207.
63. Veves A., Falanga V., Armstrong D.G., et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001, 24:290-295.
64. Schonfeld W.H., Villa K.F., Fastenau J.M., et al. An economic assessment of Apligraf (Graftskin) for the treatment of hard-to-heal venous leg ulcers. Wound Repair Regen 2000, 8:251-257.
65. Langer A., Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 2009, 9:115.
66. Fivenson D.P., Scherschun L., Cohen L.V. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast Reconstr Surg 2003, 112:584-588.
67. Falabella A.F., Schachner L.A., Valencia I.C., et al. The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. Arch Dermatol 1999, 135:1219-1222.
68. Falabella A.F., Valencia I.C., Eaglstein W.H., et al. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 2000, 136:1225-1230.
69. Phillips T.J., Manzoor J., Rojas A., et al. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol 2002, 138:1079-1081.
70. Muhart M., McFalls S., Kirsner R.S., et al. Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites. Arch Dermatol 1999, 135:913-918.
71. Waymack P., Duff R.G., Sabolinski M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. Burns 2000, 26:609-619.
72. Eaglstein W.H., Alvarez O.M., Auletta M., et al. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg 1999, 25:195-201.
73. Rheinwald J.G., Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975, 6:331-343.
74. O'Connor N.E., Mulliken J.B., Banks-Schlegel A., et al. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet 1981, 1:75-78.
75. Gallico G.G., O'Connor N.E., Compton C.C., et al. Permanent coverage of large burn wounds with autologous cultured human keratinocytes. N Engl J Med 1984, 311:448-451.
76. Hefton J.M., Caldwell D., Biozes D.G., et al. Grafting of skin ulcers with cultured autologous epidermal cells. J Am Acad Dermatol 1986, 14:399-405.
77. Carter D.M., Lin A.N., Varghese M.C., et al. Treatment of junctional epidermolysis bullosa with epidermal autografts. J Am Acad Dermatol 1987, 17:246-250.
78. Limova M., Mauro T. Treatment of pyoderma gangrenosum with cultured epithelial autografts. J Dermatol Surg Oncol 1994, 20:833-836.
79. Limova M., Mauro T. Treatment of leg ulcers with cultured epithelial autografts: treatment protocol and five year experience. Wounds 1995, 7:170-180.
80. Hefton J.M., Amberson J.B., Biozes D.G., et al. Loss of HLA-DR expression by human epidermal cells after growth in culture. J Invest Dermatol 1984, 83:48-50.
81. Thivolet J., Faure M., Demidem A., et al. Long-term survival and immunological tolerance of human epidermal allografts produced in culture. Transplantation 1986, 42:274-280.
82. Thivolet J., Faure M., Demidem A., et al. Cultured human epidermal allografts are not rejected for a long period. Arch Dermatol Res 1986, 278:252-254.
83. McGuire J., Birchall N., Cuono C., et al. Successful engraftment of allogeneic keratinocyte cultures in recessive dystrophic epidermolysis bullosa. Clin Res 1987, 35:702A.
84. De Luca M., Albanese E., Cancedda R., et al. Treatment of leg ulcers with cryopreserved allogeneic cultured epithelium: a multicenter study. Arch Dermatol 1992, 128:633-638.
85. Teepe R.G.C., Roseeuw D.I., Hermans J., et al. Randomized trial comparing cryopreserved cultured epidermal allografts with hydrocolloid dressings in healing chronic venous ulcers. J Am Acad Dermatol 1993, 29:982-988.
86. Compton C.C., Gill J.M., Bradford D.A., et al. Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. A light, electron microscopic and immunohistochemical study. Lab Invest 1989, 60:600-612.
87. Genzyme Web site Available at:, Genzyme Corporation. Accessed May 23, 2010. http://www.genzyme.com/.
88. Avita Medical Web site Available at:, Accessed May 26, 2010. http://www.avitamedical.com/.
89. Wood F.M. Clinical potential of autologous epithelial suspension. Wounds 2003, 15:16-22.
90. Globe Newswire Web site Modex Updates on Internal Programs: EpiDex and BioDelivery Available at:, Accessed June 4, 2010. http://www.globenewswire.com/newsroom/news.html%3Fd%3D17715.
91. Limova M. Cultured skin substitutes. Wound healing 2005, 42:550. Taylor & Francis, Boca Raton (FL). A. Falabella, R. Kirsner (Eds.).
92. Tausche A.K., Skaria M., Böhlen L., et al. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair Regen 2003, 11:248-252.
93. Hafner J., Kühne A., Trüeb R.M. Successful grafting with EpiDex in pyoderma gangrenosum. Dermatology 2006, 212:258-259.
94. Renner R., Harth W., Simon J.C. Transplantation of chronic wounds with epidermal sheets derived from autologous hair follicles - the Leipzig experience. Int Wound J 2009, 6:226-232.
95. Lam P.K., Chan E.S., To E.W., et al. Development and evaluation of a new composite Laserskin graft. J Trauma 1999, 47:918-922.
96. Lobmann R., Pittasch D., Mühlen I., et al. Autologous human keratinocytes cultured on membranes composed of benzyl ester of hyaluronic acid for grafting in nonhealing diabetic foot lesions: a pilot study. J Diabetes Complications 2003, 17:199-204.
97. Uccioli L. A clinical investigation on the characteristics and outcomes of treating chronic lower extremity wounds using the tissuetech autograft system. Int J Low Extrem Wounds 2003, 2:140-151.
98. Myers S.R., Partha V.N., Soranzo C., et al. Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction system for keratinocyte stem cell therapy. Tissue Eng 2007, 13:2733-2741.
99. Sun T., Higham M., Layton C., et al. Developments in xenobiotic-free culture of human keratinocytes for clinical use. Wound Repair Regen 2004, 12:626.
100. Coolen N.A., Ulrich M.M.W., Middelkoop E. Future perspectives of tissue-engineered skin: xenobiotic-free culture systems. Advances in wound care 2010, 9. vol. 1:432-437. Liebert, Columbus (OH). C.K. Sen (Ed.).
101. Bullock A.J., Higham M.C., MacNeil S. Use of human fibroblasts in the development of a xenobiotic-free culture and delivery system for human keratinocytes. Tissue Eng 2006, 12:245-255.
102. Llames S.G., Del Rio M., Larcher F., et al. Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 2004, 77:350-355.
103. van Winterswijk P.J., Nout E. Tissue engineering and wound healing: an overview of the past, present, and future. Wounds 2007, 19:277-284.
104. Chipev C.C., Simon M. Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TFG β1. BMC Dermatol 2002, 2:13.
105. Rennekampff H.O., Xu W., Rodemann H.P. Fibroblast subsets for skin substitute engineering. Advances in wound care 2010, 70. vol. 1:419-424. Liebert, Columbus (OH). C.K. Sen (Ed.).
106. De Luca M., Albanese E., Megna M., et al. Evidence that human oral epithelium reconstituted in vitro and transplanted onto patients with defects in the oral mucosa retains properties of the original donor site. Transplantation 1990, 50:454-459.
107. Sen C.K. Tiny new genes called microRNAs regulate blood vessel formation. Advances in wound care 2010, 7. vol. 1:353-358. Liebert, Columbus (OH). C.K. Sen (Ed.).
108. Koyama T., Aflaki P., Vranckx J.J., et al. Gene delivery to wounds using allogenic keratinocytes. Advances in wound care 2010, 8. vol. 1:382-387. Liebert, Columbus (OH). C.K. Sen (Ed.).
109. Schechner J.S., Crane S.K., Wang F., et al. Engraftment of a vascularized human skin equivalent. FASEB J 2003, 17:2250-2256.
110. Li W.W., Talcott K.E., Zhai A.W., et al. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care 2005, 18:491.
111. Berthod F., Germain L., Pouliot R., et al. How to achieve early vascularization of tissue-engineered skin substitutes. Advances in wound care 2010, vol. 1:445-450. Liebert, Columbus (OH). C.K. Sen (Ed.).
112. Boyce S.T., Kagan R.J., Greenhalgh D.G., et al. Cultured skin substitutes reduce requirements for harvesting of skin autograft for closure of excised, full-thickness burns. J Trauma 2006, 60:821-829.
113. Clinical Trials Web site Available at:, Accessed May 23, 2010. http://clinicaltrials.gov/ct2/show/NCT00004413.
114. Gibbs S., van den Hoogenband H.M., Kirtschig G., et al. Autologous full-thickness skin substitute for healing chronic wounds. Br J Dermatol 2006, 155:267-274.